Agenus to Participate in 4th Annual Evercore ISI HealthCONx Conference
17 November 2021 - 02:30PM
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an
extensive pipeline of checkpoint antibodies, adjuvants, and
vaccines designed to activate immune response to cancers and
infections, today announced that Dr. Garo Armen, Chairman and Chief
Executive Officer of Agenus and Dr. Steven O’Day, Chief Medical
Officer, will participate in a fireside chat hosted by Evercore on
Tuesday, November 30th, 2021 at 1:50 PM EST.
Registration can be completed in advance at:
https://wsw.com/webcast/evercore21/agen/2323050.
A replay will be available after the call on the Events &
Presentations page of the Agenus website at
https://investor.agenusbio.com/events-and-presentations.
About AgenusAgenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer. The
Company's vision is to expand the patient populations benefiting
from cancer immunotherapy by pursuing combination approaches that
leverage a broad repertoire of antibody therapeutics, adoptive cell
therapies (through its affiliate MiNK Therapeutics), adjuvants, and
proprietary cancer vaccine platforms. The Company is equipped with
a suite of antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support clinical
programs. Agenus is headquartered in Lexington, MA. For more
information, please visit www.agenusbio.com and our Twitter handle
@agenus_bio. Information that may be important to investors will be
routinely posted on our website and Twitter.
Forward-Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements relating to our technologies, therapeutic candidates,
and capabilities, for instance, statements regarding therapeutic
benefit and efficacy, mechanism of action, potency, durability, and
safety profile of our therapeutic candidates, both alone and in
combination with each other and/or other agents; statements
regarding future plans, including research, clinical, regulatory,
and commercialization plans; and any other statements containing
the words "may," "believes," "expects," "anticipates," "hopes,"
"intends," "plans," "will" and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially. These risks and uncertainties
include, among others, the factors described under the Risk Factors
section of our most recent Quarterly Report on Form 10-Q or Annual
Report on Form 10-K filed with the Securities and Exchange
Commission. Agenus cautions investors not to place considerable
reliance on the forward-looking statements contained in this
release. These statements speak only as of the date of this press
release, and Agenus undertakes no obligation to update or revise
the statements, other than to the extent required by law. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement.
ContactAgenus Inc.Divya
Vasudevan, PhD781-674-4571divya.vasudevan@agenusbio.com
Agenus Media RelationsKimberly HaKKH
Advisors917-291-5744kimberly.ha@kkhadvisors.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
Von Mär 2023 bis Mär 2024